Boston Scientific (BSX) Physician Check Downplays TAVR Sales Headwind - Stifel
Tweet Send to a Friend
Stifel analyst Rick Wise reiterated a Buy rating and $47.00 price target on Boston Scientific (NYSE: BSX) after speaking with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
